DOSAGE FORMS & SAFETY
Injections, oral medicines, patches and modified release: dosage form is identity
The same active ingredient does not necessarily mean the same medicine. Dosage form, route, strength, presentation and market are part of every comparison.
Move beyond the medicine name
Photo identification and a medicine search should not return a non-proprietary name alone. An identifiable medicine record needs a brand or non-proprietary name, active ingredient, dosage form, strength, route, target market and label version. FDA and EMA terminology treats dosage form, route and container as important product fields. A powder for injection, an oral modified-release tablet and a transdermal system are different product presentations for regulatory and use purposes.
Oral solid products need more than a tablet-or-capsule label
Immediate-release tablets, capsules, chewable tablets, orally disintegrating tablets, enteric-coated products, delayed-release products and modified-release products include information about where or how quickly a medicine is released. FDA labelling guidance and the Orange Book preface explain why changing the physical state of a modified-release product can affect release characteristics. Products with the same ingredient and stated strength cannot be assumed interchangeable from a name alone. Check the current label and a pharmacist before splitting, chewing, opening a capsule or taking it with food.
For injections, read sterility, concentration, reconstitution and route together
Injection is not a complete product identity. A product may be a solution, suspension, emulsion, liposomal product or powder requiring reconstitution or dilution, and may be intended for intravenous, subcutaneous, intramuscular or another route. These routes bring different preparation, administration, storage and monitoring requirements. A photographed pack should leave concentration, container, reconstitution instructions, route and market as fields to verify rather than grouping all injections as comparable.
Patches and transdermal systems can look similar while key parameters differ
Patches, topical medicines and transdermal delivery systems are not interchangeable categories. FDA guidance on transdermal and related systems addresses design, manufacture and lifecycle management; residual medicine, adhesion, pack integrity and wear time can all matter to safety. Public information for some hormone transdermal products also notes a possible risk of transfer by skin contact. Check the exact product label for site, duration, replacement, disposal and risk information.
Why dosage form changes originator, generic and comparison questions
Originator relationships, reference products and generic pathways must correspond to a particular active ingredient, strength, dosage form and route. The FDA Orange Book describes specific boundaries for equivalence evaluations of products with the same ingredient but different delayed- or modified-release characteristics. EMA also publishes pharmacokinetic and clinical guidance for modified-release oral, injectable and transdermal forms. OriginDrug therefore treats form and market as filters before comparison; when product information, prices, administration convenience or storage conditions are not aligned, it does not generate a ‘better’ or ‘cheaper’ conclusion.
What a photograph can and cannot do
The first-release photo feature keeps the image on the device and uses visible pack text only to find candidate records. It does not authenticate a product, verify approval or originator status, establish the indication, or give a personal-use recommendation. If a future recognition service is separately authorised, results should still show candidates, confidence boundaries and fields to check: product name, form, strength, market, batch or regulatory number, and label version. When these fields are unavailable, directing the reader to an official database and pharmacist is safer than an apparently certain conclusion.
PRIMARY REFERENCE
Source evidence
Each entry identifies its market, document type, access mode and most recent review date. Public access does not make a document applicable to every market or person. Read the review method.
- FDA: Dosage Forms ↗reviewed 2026-08-20
- FDA: Orange Book Preface ↗reviewed 2026-08-20
- FDA: Administration instructions for modified-release dosage forms ↗reviewed 2026-08-20
- FDA: Residual Drug in Transdermal and Related Drug Delivery Systems ↗reviewed 2026-08-20
- EMA: Modified-release dosage forms ↗reviewed 2026-08-20
- EMA: Manufacture of the finished dosage form ↗reviewed 2026-08-20